Rodica Pop-Busui, MD, PhD, is a professor and the chief of the division of endocrinology, diabetes, and clinical nutrition, department of medicine, Oregon Health and Science University.

Rodica Pop-Busui, MD, PhD | Image Credit: Cardiometabolic Health Congress

 and HF, according to a secondary analysis of the phase 3b SOUL trial.

HF is among the most prevalent cardiovascular complications in patients with T2D, affecting roughly 57% of the 462 million individuals with T2D worldwide. Patients with T2D and HF also have a higher risk for hospitalization and mortality compared to those with T2D without HF. Given these factors, several previous clinical trials have evaluated the efficacy of multiple GLP-1 receptor agonists to reduce the risk of major adverse cardiovascular events.

“The aim of this secondary analysis of the SOUL trial was to evaluate the effect of oral semaglutide compared with placebo on HF and ASCVD outcomes in participants with or without a history of HF at baseline,” Rodica Pop-Busui, MD, PhD, professor and chief of the division of endocrinology, diabetes, and clinical nutrition, department of medicine, Oregon Health and Science University, and colleagues wrote.

SOUL was a double-blind, randomized, placebo-controlled, event-driven, phase 3b cardiovascular outcomes trial conducted across 444 centers in 33 countries. It compared oral semaglutide 14 mg daily to placebo, both of which were administered on top of standard of care, among patients with T2D and established 

atherosclerotic cardiovascular disease (ASCVD)

A total of 9650 patients were enrolled in the SOUL trial and randomly assigned in a 1:1 ratio to once-daily treatment with either oral semaglutide or matching placebo. To avoid adverse gastrointestinal symptoms due to semaglutide treatment, patients in both arms followed a blinded dose-escalation regimen, beginning with 3 mg oral semaglutide or placebo for 4 weeks, followed by 7 mg for 4 weeks and then 14 mg for the remainder of the trial. Trial visits occurred at weeks 4, 8, and 13 after randomization and roughly every 13 weeks afterwards.

The SOUL trial ultimately saw primary-outcome events occur in 579 of the 4825 participants in the oral semaglutide group versus 668 of the 4825 participants in the placebo group (HR, 0.86; 95% CI, 0.77-0.96; 

 = .006). Confirmatory secondary outcomes did not differ significantly between the groups.

This secondary analysis included a main prespecified outcome of time to the first occurrence of a centrally adjudicated composite HF outcome, comprising HF events – including HF hospitalization or urgent HF visits – or cardiovascular death. Changes from baseline to week 104 of SOUL in clinical parameters, including HbA1c, body weight, high-sensitivity C-reactive protein (hsCRP), and systolic and diastolic blood pressure, were also prespecified secondary outcomes.

Of the 9650 patients enrolled in SOUL, 2229 (23.1%) had a history of HF – 991 with preserved ejection fraction (HFpEF), 592 with reduced ejection fraction (HFrEF), and 646 with an unknown subtype. Among participants with HF at baseline, the hazard ratio for risk of the composite HF outcome with oral semaglutide versus placebo was 0.78 (95% CI, 0.63-0.96), and was 1.01 (95% CI, 0.84-1.2) for those without HF at baseline (

Among HF subtypes, patients with HFpEF had an HR of 0.59 (95% CI, 0.39-0.86), while those with HFrEF saw an HR of 0.98 (95% CI, 0.7-1.38). The team found no heterogeneity in the risk reduction of major adverse cardiovascular events with oral semaglutide in patients with a history of HF (HR, 0.83; 95% CI, 0.68-1.01) or without (HR, 0.86; 95% CI, 0.75-0.98) (

 = .77). Serious adverse event occurrence among patients with HF was similar with oral semaglutide (n = 594) and placebo (n = 642).

“Given the high prevalence of HF (and particularly HFpEF) in people with T2D and in those with obesity, these data provide additional information for clinicians when considering therapy choices and impact on HF outcomes in people with or without known HF,” Pop-Busui and colleagues wrote. “Compared with those without T2D, individuals with HFpEF and T2D exhibit worse prognosis, likely driven by higher burden of comorbidities, underlying microvascular dysfunction, insulin resistance, autonomic imbalance, and mitochondrial abnormalities.”

Pop-Busui R, Rasmussen S, Deanfield JE, et al. Oral semaglutide and heart failure outcomes in persons with type 2 diabetes. 

McGuire DK, Busui RP, Deanfield J, et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. 

McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. New England Journal of Medicine. 2025;392(20):2001-2012. 

Articles

Secondary analysis of the phase 3b SOUL cardiovascular outcomes trial suggests oral semaglutide 14 mg may reduce a composite of heart failure (HF) events or cardiovascular death in patients with type 2 diabetes and baseline HF, with signal concentrated in HFpEF. SOUL enrolled 9650 high-risk patients with established ASCVD and/or CKD, using blinded dose escalation to mitigate GI toxicity. While overall MACE benefit was consistent regardless of HF history, confirmatory secondary endpoints were neutral, and safety in HF appeared comparable to placebo.

This secondary analysis of the phase 3b SOUL cardiovascular outcomes trial indicates oral semaglutide’s potential capacity to reduce HF events.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Jessica Mellinger, MD, is a senior staff hepatologist at Henry Ford Health.

Amanda Van Jacobs, MS, RDN, LDN, CCTD, is a transplant dietician at Rush University Medical Center.

Liver Lineup: Nutrition, Alcohol, and Liver Health in the New Dietary Guidelines

Liver Lineup: Updates and Unfiltered Insights

, hosts Nancy Reau, MD, and Kimberly Brown, MD, are joined by 2 experts from their respective institutions to unpack the implications of the newly released US Dietary Guidelines and what they mean for patients with liver disease. Amanda Van Jacobs, MS, RDN, a transplant dietitian at Rush University Medical Center, and Jessica Mellinger, MD, a transplant hepatologist at Henry Ford Health specializing in alcohol-associated liver disease, offer a nuanced, clinically grounded discussion that moves beyond headlines to practical patient care.

The conversation opens with a breakdown of what has changed in the most recent dietary guidelines, including the shift in visual messaging from the familiar “MyPlate” to a new inverted pyramid. Van Jacobs highlights one of the most consequential updates for hepatology: a substantial increase in recommended protein intake, a change with important implications for patients with cirrhosis, sarcopenia, and metabolic dysfunction-associated steatotic liver disease (MASLD).

At the same time, the panel grapples with internal inconsistencies in the guidelines, including the prominent placement of red meat, full-fat dairy, butter, and beef tallow alongside continued recommendations to limit saturated fat to < 10% of daily calories.

A major throughline of the discussion is the guidelines’ strongest and clearest message: reduce ultra-processed foods. Van Jacobs and Brown emphasize the need to educate patients on what “ultra-processed” actually means, distinguishing these foods from minimally processed options such as frozen vegetables or packaged nuts. The group underscores that without this context, visual guidelines risk being misinterpreted, leading patients to add recommended foods on top of an already calorie-dense, highly processed diet rather than replacing unhealthy staples.

Mellinger then turns the focus to alcohol guidance, which she describes as notably sparse. While the updated guidelines broadly recommend “drinking less,” they remove specific thresholds and fail to address liver disease directly.

Drawing on evidence from hepatology and oncology, Mellinger reinforces that there is no safe level of alcohol consumption she can recommend for patients with liver disease, and stresses the importance of individualized conversations that consider total health risk, not just cardiovascular outcomes.

Across nutrition and alcohol use, the panel converges on a shared conclusion: guidelines are a starting point, not a substitute for clinician-led education. Meaningful progress, they argue, will require clearer public messaging, earlier education, and systemic changes that address how food and alcohol are marketed, consumed, and understood.

Editors’ Note: Relevant disclosures for Reau include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal. Relevant disclosures for Mellinger include GlaxoSmithKline. Van Jacobs reports no relevant disclosures.

Brooks A. New Dietary Guidelines Draw Criticism For High Fat Dairy, Protein Recommendations. HCPLive. January 8, 2026. Accessed February 4, 2026. 

https://www.hcplive.com/view/new-dietary-guidelines-draw-criticism-high-fat-dairy-protein-recommendations

AASLD. AASLD Raises Concern Over Removal of Evidence-Based Alcohol Guidance in 2025–2030 Dietary Guidelines for Americans. January 9, 2026. Accessed February 4, 2026. 

https://www.aasld.org/aasld-raises-concern-over-removal-evidence-based-alcohol-guidance-2025-2030-dietary-guidelines

Podcasts

Reau and Brown are joined by Amanda Van Jacobs, MS, RDN, and Jessica Mellinger, MD, to discuss the new dietary guidelines through the lens of liver health.

Hepatology

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Liver Lineup: Updates & Unfiltered Insights

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice.

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Giles W. Story, PhD, from the University College London

Delay Discounting Offers No Predictive Value for MDD Relapse, With Giles Story, PhD

 who show greater impatience for delayed rewards are more likely to report residual depressive symptoms, but that behavioral trait does not predict relapse after stopping antidepressant therapy, according to new longitudinal data.

The findings suggest caution in using delay discounting as a clinical tool for guiding antidepressant discontinuation. Although this behavioral measure reflects known links between depression, impulsivity, and serotonergic function, investigators found it provided minimal predictive value in determining which patients are most likely to relapse after stopping medication.

“The bottom line is probably discounting is not going to be used like a lab test,” Giles W. Story, PhD, from the University College London, told 

Rather, clinicians use this study to guide conversations with patients about how depression may be associated with a focus on the present and challenges in planning for the future.

“We know avoidance is a big part of what maintains depression, and through that, people miss out on opportunities for longer-term rewards,” he added.

In a multi-site study led by Doron Elad, PhD, and Story, the study enrolled 97 patients with remitted MDD receiving antidepressant medication and 54 matched healthy controls across sites in Zurich and Berlin. Participants completed validated delay discounting tasks at baseline (MA1) and again after randomization to either antidepressant discontinuation or continuation, with 6 months of follow-up for relapse. Overall, 35% of patients relapsed during follow-up, while 65% remained well.

At baseline, patients with remitted MDD demonstrated significantly steeper delay discounting than controls (Cohen’s d = 0.34), indicating a greater tendency to favor immediate rewards. Delay discounting showed a modest association with depressive symptom severity, even when patients’ symptoms remained below the clinical threshold for relapse. For instance, patients were indifferent between receiving €66 immediately or €75 after a delay, whereas controls were indifferent at approximately €70.

Neither baseline discounting nor changes following antidepressant discontinuation predicted relapse during follow-up. Discontinuation led to only small increases in depressive symptoms, which may have been insufficient to shift discounting behavior.

“The effect that we saw after discontinuation of symptoms was quite small, so people's depressive symptoms did worsen slightly when they stopped medication, but these are people that already have quite low levels of symptoms, and they got just a tiny bit worse,” Story said. “It's probable that discount is probably just not sensitive enough to pick up that small change in symptoms.”

The results also challenge assumptions about behavioral markers as standalone predictors of relapse. Although residual symptoms predict relapse risk overall, they do not reliably predict whether stopping medication increases that risk.

Unexpectedly, higher baseline discounting was associated with greater symptom improvement over time.

“We thought that higher discounts at baseline might be associated with worsening of depression. The fact that we found the opposite strikes a bit of a note of caution,” Story said. “[It] could be a false positive occasionally…it's possible that there's another reason for…why discounting might be increasing depression. On the one hand… maybe that people are not willing to delay gratification, and that's actually part of something that maintains depression…On the other hand, it could be that becoming a bit more impulsive when you're depressed is actually adaptive, and it means that you can get a bit more immediate reward that boosts your mood a bit and carries you through.”

Elad D, Story GW, Berwian IM, Stephan KE, Walter H, Huys QJM. Delay discounting correlates with depression but does not predict relapse after antidepressant discontinuation. Mol Psychiatry. Published online January 8, 2026. 

Videos

Delay discounting links to residual depression symptoms but does not predict relapse after stopping antidepressant treatment in patients with remitted MDD.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Walter J. Liszewski, MD, is an associate professor of dermatology and cancer epidemiology at Northwestern University Feinberg School of Medicine.

Contact Dermatitis Updates for 2026, With Walter Liszewski, MD

, held at the Grand Wailea hotel, a session was presented titled ‘Contact Dermatitis Update 2026,’ during which the talk’s presenter highlighted the key challenges of managing a wide range of contact dermatitis issues.

This session was presented by Walter Liszewski, MD, associate professor of dermatology and cancer epidemiology at Northwestern University’s Feinberg School of Medicine. Liszewski spoke with the team at 

 about this session and what he feels are the most important elements of this talk.

“[In] patch testing, we have different Core Series,” Liszewski expressed. “These are [lists of] allergens that we set nationally for the US and Canada that will [include] the most common allergens, but they're not updated annually. What we start to see is that in between the periodic updates, which occur every 3 - 5 years, there may be new allergens that are all of a sudden becoming very relevant.”

Liszewski highlighted examples of these newly-relevant allergens, including benzisothiazolinone. He described this allergen as not included in the American Contact Dermatitis Series. Liszewski notes benzisothiazolinone’s structural similarity to methylisothiazolinone and methylchloroisothiazolinone.

However, it is used predominantly in hand soaps, dish soaps, and laundry detergents, so he urged clinicians to ask patients if their soap contains this ingredient. Later, Liszewski was also asked about the range of dermatitis dilemmas and what some of the most challenging or commonly mismanaged scenarios were, in his view.

“There are 2 major ones: The first is chronic hand eczema,” Liszewski explained. “...The second thing I talk about is chronic lip dermatitis or cheilitis; more often than not, it's not an allergy.”

To learn more about this topic and related information, view Liszewski’s full video interview posted above.

The quotes used in this video summary were edited for clarity.

Liszewski W. Contact Dermatitis Update 2026. Presented at: Maui Derm Hawaii 2026; January 25-29, 2026; Maui, Hawaii.

Schalock PC, Dunnick CA, American Contact Dermatitis Society Core Allergen Series Committee, et al. American Contact Dermatitis Society Core Allergen Series: 2020 Update. Dermatitis. 2020 Sep-Oct;31(5):279-282. 

In this Maui Derm Hawaii 2026 interview, key takeaways on contact dermatitis treatment strategies are highlighted by Liszewski.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

January 2026 opened with major momentum across hepatology, particularly in metabolic and viral liver disease. The US Food and Drug Administration (FDA)’s decision to grant Breakthrough Therapy Designation to pemvidutide marked a significant milestone for metabolic dysfunction-associated steatohepatitis (MASH), reflecting growing confidence in dual agonist strategies supported by robust histologic and noninvasive data. In parallel, long-awaited phase 3 results for bepirovirsen signaled meaningful progress toward functional cure in chronic hepatitis B, with consistent efficacy across a broad, global patient population and especially strong responses in patients with lower baseline HBsAg levels.

Beyond late-stage trial readouts, January’s updates emphasized the evolving complexity of chronic liver disease care. Expert discussions highlighted the importance of addressing stigma and integrating multidisciplinary approaches in alcohol-associated liver disease, while advances in second-line therapies continued to reshape expectations for patients with primary biliary cholangitis (PBC). Rounding out the month, forward-looking perspectives on the MASH pipeline underscored a field transitioning from uncertainty to cautious optimism as multiple novel agents advance toward clinical reality.

Check out this January 2026 hepatology month in review for a recap of HCPLive’s coverage of the top hepatic news and research from the past few weeks:

Pemvidutide Gets Breakthrough Therapy Designation for MASH

On January 5, 2026, the FDA granted Breakthrough Therapy Designation to pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, for the treatment of patients with MASH. The decision was supported by 24-week data from the IMPACT phase 2b trial demonstrating statistically significant MASH resolution without worsening of fibrosis, along with early and substantial improvements in liver fat and non-invasive tests of fibrosis and hepatic inflammation.

Bepirovirsen Meets Function Cure Endpoint in Phase 3 B-Well Trials for Hepatitis B

On January 7, 2026, GSK announced positive results from a pair of phase 3 trials, B-Well 1 and B-Well 2, evaluating bepirovirsen, an investigational antisense oligonucleotide, for the treatment of chronic hepatitis B in > 1800 patients from 29 countries. Both trials met their primary endpoint and bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate. Of note, results were statistically significant across all ranked endpoints, including in patients with HBsAg <=1000 IU/ml where an even greater effect was demonstrated.

Addressing Stigma and Advancing Care in Alcohol-Associated Liver Disease, With Frances Lee, MD

Alcohol-associated liver disease remains a major and growing cause of liver-related morbidity and mortality, yet it is often approached through an oversimplified and stigmatized lens.

Misconceptions about who develops the disease, why it occurs, and how it should be treated continue to influence both patient engagement and clinical decision-making. With evolving understanding of the disease, Frances Lee, MD, describes increasing recognition that effective care extends beyond managing liver injury alone and requires a more nuanced, multidisciplinary approach.

Closing Gaps in PBC Care With Emerging and Established Second-Line Treatments

The therapeutic landscape for PBC has undergone a meaningful transformation in recent years, offering new optimism for a disease long defined by limited treatment options. A. Sidney Barritt, MD, and Frances Lee, MD, review recent therapeutic progress, ongoing challenges, and what they foresee for the future of PBC management.

MASH Pipeline Developments and Emerging Therapies to Watch in 2026, With Mazen Noureddin, MD, MHSc

After years of setbacks and uncertainty, the therapeutic landscape for MASH has entered a decisive new phase. Once characterized by failed trials and a lack of approved therapies, the field has rapidly shifted toward cautious optimism, driven by regulatory clarity, advancing endpoints, and a deepening late-stage pipeline.

Mazen Noureddin, MD, MHSc, recaps recent progress in MASH therapeutic development and looks ahead to what 2026 and beyond may offer.

HCPLive_Horizontal_VideoThumbnails Logan Briggs (2).png

Catch up on hepatic FDA news, expert insights on PBC and MASH developments, & more.

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

5 Hepatology Headlines You Missed in January 2026

Susanne Brix Pedersen, professor at DTU Bioengineering

Longitudinal data identify aromatic lactate–producing bifidobacteria and the metabolite 4-hydroxy-phenyllactate as key factors in early immune tolerance.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Early-Life Bifidobacteria Linked to Lower Food Allergy Risk, With Susanne Brix Pedersen

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

January 2026 Hematology Month in Review highlights new ASH and KDIGO guidelines, FDA approvals, and pipeline progress in rare blood disorders.


Hematology

6 Hematology Headlines You Missed in January 2026 

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

FDA approvals, priority review decisions, and new data on treatment response and mechanisms highlight a month of progress in MDD and ADHD.

6 Psychiatry Headlines You Missed in January 2026

Eingun James Song, MD, is the director of clinical research for Frontier Dermatology. 

This interview at Maui Derm 2026 highlights notable takeaways regarding psoriasis treatment strategies and emerging therapies.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Discussing Psoriasis Treatment Updates for 2026, With Eingun James Song, MD

Paul Sorajja, MD, is the associate director of the Banner – University Medicine Heart Institute and professor of medicine at the University of Arizona. 

Sorajja describes his team’s operation to implant the ring via a novel trans-septal system, effectively avoiding the need to stop the heart in MR treatment.

Structural Heart Disease

First-in-America Implantation of AMEND Annuloplasty Ring in Mitral Regurgitation, With Paul Sorajja, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

In this analysis presented at Maui Derm, indirect comparisons were made between risankizumab and icotrokinra in patients with psoriasis.

Risankizumab Compared to Icotrokinra in Adult Patients with Psoriasis

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

January 2025 saw new data and guidelines in asthma, COPD, and pulmonary fibrosis.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonary Fibrosis

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

7 Pulmonology Headlines You Missed in January 2026

FDA clears pediatric HAE oral therapy as intranasal epinephrine and heat-treated peanut/egg OIT studies point to safer allergy care.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

7 Allergy Headlines You Missed in January 2026

Eliezer Katz, MD, is the chief medical officer at Eledon Pharmaceuticals. 

Eliezer Katz, MD, says investigational anti-CD40L therapy tegoprubart shows promise as a non-calcineurin inhibitor option for adult de novo kidney transplant patients

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

2-Year Phase 1b Tegoprubart Preserves Kidney Function in Transplant Recipients,  With Eliezer Katz, MD

David Golden, MD, clinical associate professor of medicine at Johns Hopkins University School of Medicine.

Despite usability concerns cited by the FDA, investigators say dibutepinephrine’s needle-free, portable design could still address gaps in real-world epinephrine use.

Latest News

Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D

Liver Lineup: Nutrition, Alcohol, and Liver Health in the New Dietary Guidelines

Delay Discounting Offers No Predictive Value for MDD Relapse, With Giles Story, PhD

Contact Dermatitis Updates for 2026, With Walter Liszewski, MD

5 Hepatology Headlines You Missed in January 2026